DISCOVER TOOLS TO PROGRESS CANDIDATES TO THE CLINIC & AVOID COSTLY FAILURES
Thank you to our speakers, sponsors, and delegates who joined us in San Francisco for the summit!
If you are interested in the 2025 event, please get in touch!
Implementing State-of-the-Art, Reproducible Preclinical Oncology Models to
Accelerate Your Candidate’s Clinical Translatability
Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, set an exciting precedent during 2023. However, the translation rates of oncology therapeutics into the clinic remain at 20%, proving there remained a large unmet need for tools to support drug development efforts in a patient-specific context at the preclinical and early translational levels.
At the 8th Annual Tumor Models San Francisco Summit, attendees gained practical insights into the latest updates across the West Coast and beyond through 25+ case studies that empowered their candidate selection workflows. They joined us to learn from and meet pioneers in preclinical and translational oncology which accelerated candidate’s clinical translatability with optimized efficiency, and cost-effectiveness!
Discover the rationale Amgen, IGM Biosciences, Rondo Therapeutics, and more implement across their model selection criteria to empower you to streamline your model selection processes. | |
Revolution Medicines spotlight the potential of genetically engineered models to enhance the therapeutic potential of RAS-targeted inhibitors | |
RAPT Therapeutics interrogate immune resistance mechanisms within tumor models to support checkpoint inhibitor therapeutic assessments | |
Arsenal Biosciences demonstrate the applications of tumor models in cell therapy program development across multiple cancer indications | |
Characterize the complexities of the components of the tumor microenvironment by leveraging spatial biology and digital pathology tools with Takeda |
Our 2024 Expert Speakers Included:
Ksenya Shchors
Senior Director - Scientific Strategy, Cell Therapy & Immuno-Oncology
Astellas Innovation Management LLC